AstraZeneca's Wainua — a once-a-month injection for a rare, usually fatal heart condition called ATTR-CM — just failed its big trial. Investors reacted like it was an asteroid strike: the stock dropped nearly 10% and wiped out roughly £19 billion before most of London had finished its coffee. * Bloomberg's headline: "AstraZeneca Shares Fall as Wainua Fails to Cut Deaths in Heart Condition Trial." Grammar quiz: what's the subject of that sentence? Shares. What's tucked into the "as" clause, doing the actual dying? People. * It's a bit like headlining a wedding "Caterer Loses Contract" and mentioning, almost in passing, that the wedding also got called off. Technically both things happened. One of them is clearly the story. * The trial enrolled 1,432 people with a disease that quietly turns their own heart muscle to sludge. Wainua didn't beat placebo at keeping them alive longer. That's not a footnote to a stock chart — the stock chart is a footnote to that. * Bloomberg's £19-billion number isn't fake. It's real, it's news, pensions and index funds genuinely felt it. But a headline gets to pick who's the main character, and Bloomberg picked the shares over the 1,432 people the drug was actually supposed to help.